A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager". This type of immunotherapy ignites our own ...

An ultrasound-based treatment for prostate cancer showed better safety and operative metrics versus robotic radical ...

Watchdog finds failings in prostate cancer treatment in North Wales going back almost a decade.

“This is a rare opportunity for me personally, this is my only hope to extend my life by any real period at all." The post ...

Brian Holmes is the first man in the UK and the fifth in the world to receive the treatment.

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...

Pfizer Inc. PFE shares are up during Thursday’s trading session after the company shared data from Talzenna plus Xtandi’s investigational treatment regimen for HRR gene-mutated metastatic ...

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

Talzenna plus Xtandi showed a 14-month survival improvement for HRR gene-mutated metastatic castration-resistant prostate cancer, supported by TALAPRO-2 trial data. Nubeqa approval for metastatic ...

Read more about the factors that patients with prostate cancer value most in treatment decisions, as reported at EAU 2026.

GRAND RAPIDS, Mich. — One in eight men will be diagnosed with prostate cancer in their lifetime. Typically, treatment includes hormone medication, and when that fails, chemotherapy. BAMF Health in ...

Germline testing can identify hereditary cancer, which leads to implications for family members, cascade testing for relatives, and starting surveillance and prevention measures: Genetic testing in ...